DUAVEE Clinical Results: Significant Hot Flash Reduction at Week 12 #3388852 (License: Personal Use)

The infographic highlights that DUAVEE patients experienced an average of 2.7 fewer moderate-to-severe hot flashes per day than placebo users, with a 0.6-point greater reduction in severity score (on a 1-3 scale). Frequency dropped from 10.3 to 2.8 daily hot flashes (74% reduction), outperforming placebo’s 51% reduction; severity decreased by 39% versus 14% for placebo. Data are based on mathematical means, not statistical analysis.

Used in pharmaceutical marketing or medical education pages to communicate clinical trial outcomes for DUAVEE (a conjugated estrogens/bazedoxifene therapy) targeting menopausal symptoms; aligns with user intent seeking evidence-based treatment efficacy.